Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

SK Pharmteco acquires the Center for Breakthrough Medicines

by Rick Mullin
September 29, 2023 | A version of this story appeared in Volume 101, Issue 32

 

SK Pharmteco, a US-based subsidiary of South Korea’s SK, has acquired a controlling interest in the Center for Breakthrough Medicines (CBM), a cell-and-gene-therapy contract development and manufacturing organization (CDMO) in King of Prussia, Pennsylvania. The move follows SK Pharmteco’s $350 million investment in CBM in 2022 and its acquisition of Yposkesi, a viral vector CDMO based in Évry-Courcouronnes, France, in 2021. SK Pharmteco intends to merge the two operations.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.